Trial Profile

Dosing of Various Multi Kinases Inhibitors Plasma Concentrations for Patients Treated for Their Advanced Digestive Cancer, With the Aim to Determine the Best Optimal Dose for Each Treatment, in the Future

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary) ; Cetuximab (Primary) ; Encorafenib (Primary) ; Everolimus (Primary) ; Regorafenib (Primary) ; Sunitinib (Primary)
Indications Colorectal cancer; Gastrointestinal stromal tumours; Liver cancer; Neuroendocrine tumours; Pancreatic cancer
Focus Pharmacokinetics
Acronyms TARGETMONITO

30 Aug 2022 Planned primary completion date changed from 1 Jun 2026 to 1 Aug 2026.
30 Aug 2022 Status changed from not yet recruiting to recruiting.
08 Jul 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com